title: Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-β-cyclodextrin complex.
abstract: Aprepitant (APR), a neurokinin 1 receptor antagonist, is an approved treatment for chemotherapy-induced nausea and vomiting and for post-operative nausea and vomiting. However, it has poor water solubility. This study was performed to optimize the capsule formulation of an inclusion complex of APR with sulfobutyl ether-β-cyclodextrin (SBE-β-CD), and to evaluate its water solubility, dissolution rate, and bioavailability. The complex was prepared through the saturated-aqueous solution method and then characterized by Fourier transform infrared spectroscopy, x-ray powder diffraction, and differential scanning calorimetry. Subsequently, a pharmacokinetic study was performed using liquid chromatography-tandem mass spectrometry. Emend, which features an innovative formulation that incorporates drug nanoparticles with high bioavailability, was used as a reference for comparison with the optimized formulation. As a result, the dissolution rates and extent of release of the test formulation in various media were enhanced relative to those of Emend. The bioavailability of the drug complex was comparable to that of Emend. In summary, the SBE-β-CD complexation could provide a practical and cost-effective option for enhancing the solubility and bioavailability of APR according to our research.
authors.affiliation: School of Pharmaceutical Sciences, Nanjing University of Technology, 5th Mofan Road, Nanjing, 210009, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Ren
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhou
authors.forename: Ping
authors.initials: P
authors.lastname: Wei
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Guoguang
authors.initials: G
authors.lastname: Chen
mesh_terms: D000818:Animals; D000077608:Aprepitant; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning / Q000379:methods; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002853:Chromatography, Liquid / Q000379:methods; D004285:Dogs; D009025:Morpholines / Q000737:chemistry* / Q000493:pharmacokinetics*; D053758:Nanoparticles / Q000737:chemistry; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared / Q000379:methods; D053719:Tandem Mass Spectrometry / Q000379:methods; D014961:X-Ray Diffraction / Q000379:methods; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D009025:Morpholines; D047392:beta-Cyclodextrins; D000077608:Aprepitant; C093196:SBE4-beta-cyclodextrin